Merck says Phase 3 trial shows tulisokibart meets primary endpoint in ulcerative colitis study

Merck & Co., Inc.

Merck & Co., Inc.

MRK

0.00
  • Merck reported positive topline results from its Phase 3 ATLAS-UC induction-only study of tulisokibart in moderately to severely active ulcerative colitis.
  • The trial met the primary endpoint on clinical remission at 12 weeks, also achieving key secondary goals, supporting a potential new biologic option.
  • No new safety signals were identified, consistent with earlier mid-stage studies.
  • Results have not yet been presented; Merck expects to present them at an upcoming scientific congress, alongside data from an ongoing induction and maintenance study.
  • The readout strengthens Merck’s position in the emerging anti-TL1A class, where tulisokibart is being tested across multiple inflammatory indications.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606220645BIZWIRE_USPR_____20260622_BW057174) on June 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.